The Orphan Drug Act of 1983 has been instrumental in the development of treatments for rare diseases, with over half of the new drugs approved by the FDA in 2024 being for such conditions. This law provides financial incentives to companies that develop treatments for rare diseases, which are defined as those affecting fewer than 200,000 people in the United States.

Rare Disease Research on the Rise

The number of orphan drug designations has increased significantly since the law was passed, with 6,340 designations granted between 1983 and 2022. This has led to the development of treatments for 392 rare conditions, with many more in the pipeline. The focus on rare disease research has also led to advances in the understanding and treatment of more common diseases, as many rare diseases share underlying biology with more common conditions.

Despite the success of the Orphan Drug Act, there are still thousands of rare diseases without approved treatments. The law has been criticized for allowing companies to game the system by seeking orphan designation for drugs that also treat more common conditions. Additionally, the high cost of many orphan drugs has made them inaccessible to some patients.

Impact on Patients and Families

The Orphan Drug Act has had a significant impact on patients and families affected by rare diseases. Many of these diseases were previously without treatment options, and the law has provided hope for those affected. However, the high cost of many orphan drugs remains a challenge, and there is a need for continued innovation and access to these treatments.

Original reporting: El Paso News (HLL/CB) — read the source article.